- Previous Close
13,620.65 - Open
13,850.00 - Bid --
- Ask --
- Day's Range
13,200.05 - 14,200.00 - 52 Week Range
3,611.10 - 16,524.95 - Volume
41,963 - Avg. Volume
49,503 - Market Cap (intraday)
171.322B - Beta (5Y Monthly) 0.99
- PE Ratio (TTM)
51.06 - EPS (TTM)
261.52 - Earnings Date Nov 6, 2024
- Forward Dividend & Yield 14.00 (0.10%)
- Ex-Dividend Date Jul 12, 2024
- 1y Target Est
--
Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
www.neulandlabs.com1,643
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: NEULANDLAB.NS
View MoreResearch Reports: NEULANDLAB.NS
View MorePerformance Overview: NEULANDLAB.NS
Trailing total returns as of 10/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NEULANDLAB.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NEULANDLAB.NS
View MoreValuation Measures
Market Cap
174.74B
Enterprise Value
174.67B
Trailing P/E
52.00
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.98
Price/Book (mrq)
13.62
Enterprise Value/Revenue
10.97
Enterprise Value/EBITDA
33.46
Financial Highlights
Profitability and Income Statement
Profit Margin
20.55%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
16.35B
Net Income Avi to Common (ttm)
3.36B
Diluted EPS (ttm)
261.52
Balance Sheet and Cash Flow
Total Cash (mrq)
875.75M
Total Debt/Equity (mrq)
7.44%
Levered Free Cash Flow (ttm)
--